California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics, a muscle disease company developing therapeutics for people living with genetically-driven diseases. 3 September 2024
UK-based Amphista Therapeutics—which calls itself a leader in next generation targeted protein degradation (TPD) approaches—has named Antony Mattessich its new chief executive (CEO) and member of the board of directors. 3 September 2024
Texas, USA-based Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of chief executive (CEO) effective November 1, 2024. 22 August 2024
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
California, USA-based clinical-stage biopharmaceutical company 89bio has appointed Francis Sarena as chief operating officer (COO), effective August 5, 2024. 20 August 2024
USA-based biotech Tiziana Life Sciences today announced the appointment of Ivor Elrifi as its chief executive (CEO), effective immediately. 19 August 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
SpyBiotech, a UK biotech with a novel vaccine platform technology that can target infectious diseases, cancer and chronic diseases, has appointed Prakash Bhuyan as chief medical officer (CMO). 12 August 2024
US gene therapy company Regenxbio has announced that co-founder Kenneth Mills is to step down as president and chief executive following 15 years of leadership at the company. 12 June 2024
Dr Michaela Eikermann has now taken up the position of deputy director of Germany’s watchdog the Institute for Quality and Efficiency in Health Care (IQWiG). 10 June 2024
UK-based AI-driven precision medicines company Exscientia today announced the appointment of two technology and clinical development leaders to senior roles. 6 June 2024
Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation announced that it has appointed Aaron Berg, currently Amarin’s executive vice president and president of the US business, as president and chief executive (CEO). 5 June 2024
After more than 30 years with neuroscience-focused biopharma Neurocrine Biosciences, founder and chief executive Kevin Gorman is to retire in October - albeit staying on as a board member. 29 May 2024
The Bill & Melinda Gates Medical Research Institute (Gates MRI) has appointed Patrice Matchaba, as chief executive (CEO), starting June 10, 2024. 29 May 2024
Sapreme, a Dutch biotech developing next-generation RNA therapeutics for genetically-driven diseases, has appointed Marco Timmers as chief executive. 28 May 2024
Swiss pharma giant Roche on Monday announced today that James Sabry, head of Roche pharma partnering, will be retiring after 14 years with the company. 28 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief medical officer (CMO). 23 May 2024